Challenges and opportunities for use of cost-effectiveness analysis

J Natl Cancer Inst. 2009 Sep 2;101(17):1161-3. doi: 10.1093/jnci/djp258. Epub 2009 Aug 7.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Canada
  • Cetuximab
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / economics*
  • Cost-Benefit Analysis
  • Drug Costs
  • Health Care Costs
  • Humans
  • Mutation*
  • Patient Selection*
  • Proto-Oncogene Proteins / analysis*
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins p21(ras)
  • Quality-Adjusted Life Years
  • United Kingdom
  • United States
  • ras Proteins / analysis*
  • ras Proteins / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • Cetuximab